Ciprolet for cystitis

Inflammation of the bladder usually occurs due to bacteria entering it, so antibacterial agents are used to treat it, including Ciprolet prescribed for cystitis.

Other trade names of this drug, i.e. synonyms: Ciprofloxacin, Cipro, Cipriol, Ciprolac, C-flox, Ciprinol, Tsifran, Medociprin, etc.

Indications Ciproleta for cystitis

Considering the fairly wide spectrum of bactericidal action of Ciprolet on aerobic gram-negative and gram-positive bacteria, indications for its use include infectious (bacterial) inflammations of the eyes, ENT organs and respiratory organs, genitourinary system, intestines, abdominal organs and pelvis, bone and joint infectious diseases, as well as bacteremia, bacteriuria and primary sepsis. [ 1 ]

Can Ciprolet be used for cystitis? The appropriateness of using this antibacterial agent is determined by the attending physician - based on the results of a microbiological study (bacterial culture) of urine, which ensures the identification of the pathogen. Antimicrobial agents of the second-generation fluoroquinolone group, which include the active substance of Ciprolet - ciprofloxacin hydrochloride, are not used for empirical therapy of cystitis, but are used when other antibiotics are insufficiently effective.

In addition, antibiotic therapy is not indicated for interstitial, drug-induced, radiation-induced inflammation of the bladder, as well as cystitis that occurs with other diseases (diabetes, nephrolithiasis, spinal cord injury).

Read - Antibiotics for cystitis. [ 2 ], [ 3 ]

Ciprolet for cystitis in women is prescribed under the same conditions, taking into account that in almost 80% of cases, inflammation of the bladder and urinary tract is caused by bacteria from the intestines and lower urinary tract, since the area of the female genital organs often contains bacteria that can cause cystitis. Urologists classify Escherichia coli as causative agents of cystitis, as well as Enterobacter cloacae, Klebsiella spp., Proteus spp., Pseudomonas aeruginosa, Staphylococcus saprophyticus.

Release form

Ciprolet is available in the following forms: tablets (0.25 and 0.5 g), infusion solution (in 100 ml bottles), eye drops (in 5 ml bottles).

Pharmacodynamics

The active substance of the drug Ciprolet is a synthetic antibiotic of the fluoroquinolone group of the second generation, ciprofloxacin (in the form of hydrochloride), which is a bicyclic fluorinated derivative of quinolinecarboxylic acid.

The basis of its pharmacological action, leading to the death of pathogenic microorganisms (bactericidal effect), is the ability to specifically and irreversibly suppress the topoisomerase enzymes of bacterial cells (DNA topoisomerases II and IV), which ensure the replication of their DNA, protein synthesis and reproduction by division.

Pharmacokinetics

After oral administration of Ciprolet, ciprofloxacin hydrochloride is rapidly absorbed from the gastrointestinal tract and reaches peak plasma levels within one to one and a half hours. Blood albumin binding does not exceed 30%, although the average bioavailability is 70%.

Ciprofloxacin hydrochloride penetrates into almost all tissues and biological fluids of the body, overcoming the blood-brain barrier; the intra-tissue concentration is higher than in the blood and remains at a high level for 10-12 hours.

The half-life in plasma is 3-5 hours; it is excreted from the body mainly through the kidneys (unchanged) and also through the intestines.

Dosing and administration

How to take Ciprolet for cystitis? Ciprolet tablets are taken orally before meals with water. A single dose of the drug is one 0.25 g tablet. Two tablets are taken during the day (with an interval of 12 hours).

How much Ciprolet to drink for cystitis? The duration of taking the drug is determined by the doctor - based on the results of urine culture. The standard course of treatment is five to seven days.

• Application for children

Due to the risk of disruption of the development of articular cartilage tissue, fluoroquinolone antibacterial agents are contraindicated for use in children and adolescents under 18 years of age.

Use Ciproleta for cystitis during pregnancy

The use of fluoroquinolone antibiotics, including Ciprolet and its synonyms containing ciprofloxacin hydrochloride, is not permitted during pregnancy and lactation.

Contraindications

Ciprolet is not used for cystitis if the patient’s medical history includes:

• individual hypersensitivity to fluoroquinolones;
• convulsive syndrome;
• cerebral circulatory disorders;
• severe renal failure and/or severe impairment of liver enzyme function;
• hemolytic anemia with deficiency of the enzyme glucose-6-phosphate dehydrogenase;
• inflammation and degenerative changes in the tendons.

Side effects Ciproleta for cystitis

The use of Ciprolet may cause side effects in the form of:

• nausea, vomiting, abdominal pain, flatulence and diarrhea;
• headache, dizziness and increased intracranial pressure;
• sleep disturbances, anxiety, general depression, tremors; decreased attention, visual acuity and hearing, as well as disturbances of taste and smell;
• tachycardia and heart rate disturbances;
• skin itching and allergic rashes on the skin, increased sensitivity to ultraviolet radiation;
• reduction of the level of leukocytes, granulocytes and platelets in the blood;
• weakening and disruption of the integrity of tendons;
• the appearance of blood, protein, and calcium oxalate crystals in the urine;
• urination disorders with damage to the renal glomeruli.

Overdose

Overdose of Ciprolet leads to an increase in its gastrointestinal side effects, as well as the appearance of convulsions and neurotic symptoms. There is no specific antidote, treatment of individual symptoms is carried out.

Interactions with other drugs

The instructions for Ciprolet note the following interactions with other drugs:

• Ciprolet should not be taken simultaneously with antacids, Theophylline, Santuril (Probenecid), the anti-tuberculosis antibiotic Rifampicin, the selective immunosuppressant Cyclosporine, the indirect anticoagulant Warfarin;
• the simultaneous use of fluoroquinolones and drugs to lower blood sugar levels, as well as non-steroidal anti-inflammatory drugs (NSAIDs) slows down their elimination;
• It is possible to combine Ciprolet with antibiotics of the penicillin, aminoglycoside and cephalosporin groups.

Storage conditions

Ciprolet tablets should be stored in a dry place, away from light, at room temperature; solution – at a temperature not lower than +5°C and not higher than +25°C.

Shelf life

The drug is suitable for use for three years after release.

Analogues of Tsiprolet for cystitis

Pharmacotherapeutic action similar to that of Ciprolet, used in the treatment of bladder inflammation, is provided by: antibiotics of the fluoroquinolone group, for example, Levofloxacin (Levoflox), Pefloxacin (Peflacin, Pinaflox), Lomefloxacin (Lomflox, Lofox, Okacin); nalidixic acid preparations (Nevigramon, Negram); pipemidic acid preparations (Palin, Pimidel, Uropimid, Uripan, Uromidin).

Antimicrobial agents commonly used for bacterial cystitis include Nitrofurantoin (Furadonin), Co-trimoxazole, Fosfomycin (Fosmycin, Uronormine, Monural), and the cephalosporin antibiotics Ceftriaxone and Cephalexin.

Which is better for cystitis, Ciprolet or Nolitsin?

Like Ciprolet, Nolitsin (synonym Norfloxacin) is an antibiotic of the fluoroquinolone group and has the same mechanism of action and pharmacodynamics. But the bioavailability of norfloxacin, as well as binding to plasma proteins, is almost half that of ciprofloxacin. In addition, the minimum single dose of Nolitsin is higher than that of Ciprolet (0.4 g versus 0.25 g). However, longer use of Nolitsin (up to two months) is possible for patients with recurrent chronic cystitis.

Therefore, which is better for cystitis - Ciprolet or Nolitsin - is determined for each patient by a urologist.

The first FDA statements about the need to limit the use of antibacterial drugs belonging to the fluoroquinolone group due to serious side effects were made in 2016. And in early October 2018, having reviewed all the feedback from patients and doctors regarding the side effects of fluoroquinolone antibiotics, experts from the European Medicines Agency came to the conclusion that it was necessary to impose restrictions on their use.